




PHARMACEUTICAL 2021

Y-mAbs Therapeutics Inc.
Rank 225 of 402





RealRate

PHARMACEUTICAL 2021

Y-mAbs Therapeutics Inc. Rank 225 of 402



The relative strengths and weaknesses of Y-mAbs Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Y-mAbs Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 37% points. The greatest weakness of Y-mAbs Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 71% points.

The company's Economic Capital Ratio, given in the ranking table, is 79%, being 31% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	122,363
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,535
Liabilities, Non-Current	3,981
Other Assets	7,859
Other Compr. Net Income	-576
Other Expenses	2,203
Other Liabilities	2,695
Other Net Income	598
Other Revenues	20,750
Property and Equipment	1,825
Research and Development	93,697
Selling, General and Administrative Expense	44,785

Output Variable	Value in 1000 USD
Assets	132,047
Liabilities	26,211
Expenses	140,685
Revenues	20,750
Stockholders Equity	105,836
Net Income	-119,337
Comprehensive Net Income	-119,625
Economic Capital Ratio	79%